Clinical Trials · NCT01076803

Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

Name: Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Lanreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: University Hospital, Ghent
Enrollment: 40
Start date: Oct 2009
Locations: 1 site, Belgium
Primary endpoint: Percentage of responder patients.

View Lanreotide compound reference